Refocus Group, Inc. (RFCS) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Devices 산업에서 운영. 본사 소재지는 Dallas, TX, 미국. 현재 CEO는 J. Michael Judy.
RFCS 을(를) 보유 IPO 날짜 2003-03-07, 4 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $25.00.
Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert System, an investigational medical device that is in clinical trials for use in the binocular presbyopic treatment. It serves patients and eye care professionals. The company was founded in 1994 and is based in Dallas, Texas.
